Mycoplasma Infection

Mycoplasma infection in dogs refers to disease caused by bacteria belonging to the genus Mycoplasma and related genera including Ureaplasma. These unique microorganisms are the smallest self-replicating bacteria known and lack a conventional cell wall, distinguishing them from typical bacteria and making them inherently resistant to antibiotics that target cell wall synthesis. Mycoplasmas are found worldwide and can affect dogs of all ages, though they most commonly cause clinical disease in young animals, those living in crowded conditions, and dogs with compromised immune function.

Mycoplasma species naturally colonize the mucous membranes of the respiratory tract, urogenital tract, and eyes of many healthy dogs without causing disease. Under certain circumstances, including immune suppression, concurrent infections, or environmental stressors, these commensal organisms can become pathogenic and cause clinical illness. Additionally, some Mycoplasma species are primarily pathogenic and consistently cause disease when transmitted to susceptible hosts. Understanding the distinction between commensal carriage and active infection is important for appropriate diagnosis and treatment decisions.

Clinical syndromes associated with mycoplasma infection in dogs include respiratory disease, urogenital infections, polyarthritis, and conjunctivitis. Respiratory mycoplasma infection contributes to canine infectious respiratory disease complex, commonly known as kennel cough, often as a co-pathogen with viruses and other bacteria. Urogenital mycoplasma infection can cause infertility, abortion, and urinary tract disease. Polyarthritis develops when mycoplasmas spread through the bloodstream to colonize joint tissues. Each clinical syndrome requires specific diagnostic approaches and may have different treatment considerations.

Diagnosis of mycoplasma infection requires specialized laboratory testing since these organisms cannot be detected through routine bacterial culture methods. Treatment typically involves antibiotics from drug classes effective against wall-less bacteria, such as tetracyclines, macrolides, or fluoroquinolones. The prognosis for most mycoplasma infections is good with appropriate therapy, though chronic or recurrent disease can occur in some cases. Understanding mycoplasma infections helps veterinarians and owners recognize when this diagnosis should be pursued and how to manage affected dogs effectively.

Mycoplasma infections in dogs are caused by bacteria belonging to the class Mollicutes, primarily species within the genera Mycoplasma and Ureaplasma. These organisms are unique among bacteria in lacking a cell wall, the rigid outer structure that gives most bacteria their shape and serves as the target for common antibiotics like penicillins and cephalosporins. Instead, mycoplasmas are bounded only by a plasma membrane, giving them a pleomorphic appearance and inherent resistance to cell wall-targeting drugs. Their small genome size makes them dependent on host cells for many nutrients.

Numerous Mycoplasma species have been identified in dogs, with varying pathogenic potential. Mycoplasma cynos is the species most clearly associated with respiratory disease in dogs and is considered a primary pathogen capable of causing illness independent of other infections. Mycoplasma canis is commonly found in the urogenital tract and has been associated with reproductive disease and urinary tract infections. Other species including Mycoplasma spumans, Mycoplasma maculosum, Mycoplasma edwardii, and Ureaplasma canigenitalium are frequently isolated from healthy dogs but may cause disease under appropriate circumstances.

Transmission of mycoplasma between dogs occurs through direct contact with respiratory secretions, urogenital discharges, or other body fluids from infected animals. Aerosol transmission is important for respiratory species, allowing spread through coughing, sneezing, or close face-to-face contact. Venereal transmission spreads urogenital species during breeding. Puppies can acquire infection from their mothers during birth or nursing. Fomite transmission through contaminated objects, bowls, or bedding may occur over short distances, though mycoplasmas survive poorly in the environment without host cells.

Risk factors for developing clinical mycoplasma disease include crowded living conditions, stress, concurrent infections, and immunosuppression. Kennels, shelters, breeding facilities, and dog shows create environments where mycoplasma transmission is facilitated by close contact between many dogs and potential stress effects on immune function. Concurrent viral respiratory infections compromise mucosal defenses and allow mycoplasma to establish infection more readily. Dogs receiving immunosuppressive medications or having underlying immune dysfunction are more susceptible to disease from both pathogenic and normally commensal mycoplasma species.

The transition from asymptomatic colonization to clinical disease involves complex interactions between the organism, host immune response, and environmental factors. Mycoplasmas employ various mechanisms to evade host immunity, including antigenic variation that allows them to escape antibody recognition and the ability to survive within host cells where they are partially protected from immune effectors. When mucosal immunity is disrupted or systemic immunity is compromised, mycoplasmas can proliferate beyond normal commensal levels and invade tissues to cause clinical illness.

The clinical symptoms of mycoplasma infection in dogs vary considerably depending on which body system is primarily affected. Mycoplasmas can cause respiratory disease, urogenital infections, joint disease, eye infections, and occasionally other manifestations. The severity of illness ranges from mild, self-limiting disease to more significant infections requiring veterinary treatment. Recognizing the various presentations helps ensure appropriate diagnostic evaluation when mycoplasma infection is possible.

Respiratory mycoplasma infection typically presents as part of the canine infectious respiratory disease complex, producing symptoms commonly associated with kennel cough. Affected dogs develop a harsh, dry, honking cough that may be followed by gagging or retching. The cough is often triggered by excitement, exercise, or pressure on the trachea from collars or leashes. Nasal discharge, which may be clear initially and become thicker with secondary bacterial infection, accompanies the cough. Sneezing, mild lethargy, and slightly decreased appetite may occur. Most respiratory infections are self-limiting, but some dogs develop more severe lower respiratory involvement with fever, productive cough, and respiratory distress.

Urogenital mycoplasma infection produces different symptoms depending on the specific structures affected and the sex of the dog. In female dogs, mycoplasma infection can cause vaginitis with vulvar discharge, infertility, early embryonic death, abortion, and weak or failing puppies when infection involves the reproductive tract. Urinary tract involvement produces symptoms including frequent urination, straining to urinate, blood in urine, and urinary accidents in housetrained dogs. Male dogs may develop balanoposthitis (inflammation of the penis and prepuce) with discharge, or epididymitis and orchitis affecting fertility. Both sexes may experience recurrent or treatment-resistant urinary tract infections when mycoplasma is involved.

Mycoplasma polyarthritis causes joint pain and lameness when organisms spread through the bloodstream to colonize joint tissues. Affected dogs may show stiffness, reluctance to move, shifting leg lameness, or obvious pain when specific joints are manipulated. Joint swelling may be visible or palpable. The lameness is often cyclic, with periods of improvement followed by recurrence. Fever and general malaise frequently accompany the joint symptoms. Multiple joints are typically affected simultaneously or sequentially, distinguishing this from traumatic injuries affecting single joints.

Conjunctivitis caused by mycoplasma produces eye redness, discharge, squinting, and discomfort. The discharge may be watery initially, becoming more mucoid or purulent over time. Both eyes are often affected, though one may be more severely involved. The conjunctival membranes appear swollen and hyperemic. Chronic or recurrent conjunctivitis that does not respond to standard treatments should raise suspicion for mycoplasma involvement.

Systemic symptoms including fever, lethargy, decreased appetite, and weight loss may accompany any form of mycoplasma infection, particularly when disease is severe or widespread. Puppies and immunocompromised dogs may develop more severe systemic illness. The chronic, relapsing nature of some mycoplasma infections means symptoms may wax and wane over extended periods if the underlying cause is not identified and appropriately treated.

Diagnosing mycoplasma infection in dogs requires specialized testing because these organisms cannot be detected through routine bacterial culture techniques used for most bacterial infections. The lack of a cell wall and specific nutritional requirements mean that mycoplasmas require specialized culture media and conditions that are not routinely employed in standard veterinary diagnostic laboratories. Clinical suspicion combined with appropriate sample collection and testing is essential for confirming mycoplasma as the cause of disease.

Clinical history and physical examination findings guide initial suspicion of mycoplasma infection. Respiratory symptoms in dogs from high-risk environments such as shelters or kennels, recurrent urinary tract infections not responding to standard antibiotics, reproductive problems, or polyarthritis all warrant consideration of mycoplasma involvement. Physical examination characterizes the specific clinical syndrome and helps rule out other potential causes. Basic diagnostic testing including bloodwork and urinalysis may show nonspecific changes consistent with infection or inflammation.

Molecular testing using polymerase chain reaction (PCR) has become the primary diagnostic method for mycoplasma detection in many veterinary settings. PCR can identify mycoplasma DNA in respiratory secretions, urine, joint fluid, conjunctival swabs, or other clinical samples. The technique is highly sensitive and can detect organisms even when present in low numbers. Some PCR tests identify the presence of mycoplasma at the genus level, while others can distinguish between species, which may be relevant for understanding pathogenic significance. The availability of PCR testing varies between diagnostic laboratories.

Mycoplasma culture remains available at some specialized laboratories and provides definitive diagnosis along with the opportunity for antimicrobial susceptibility testing. Culture requires appropriate transport media to maintain organism viability and specialized culture conditions in the laboratory. Growth is typically slow, requiring days to weeks for colonies to develop. The technical demands of mycoplasma culture mean that false-negative results can occur, and PCR is often preferred for initial diagnosis. Serology detecting antibodies against mycoplasma has limited utility because many healthy dogs have been exposed and carry antibodies without active disease.

Treatment of mycoplasma infection in dogs centers on antibiotic therapy using drugs effective against these cell wall-deficient bacteria, combined with supportive care appropriate for the specific clinical syndrome present. The lack of a cell wall renders mycoplasmas inherently resistant to beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) and other drugs targeting cell wall synthesis. Effective drug classes include tetracyclines, macrolides, fluoroquinolones, and chloramphenicol, though regional susceptibility patterns and individual factors influence optimal selection.

Doxycycline is often considered the first-line treatment for mycoplasma infections in dogs due to good efficacy, oral bioavailability, and relatively low cost. The drug penetrates tissues well and achieves effective concentrations at common sites of mycoplasma infection including respiratory mucosa and joint fluid. Treatment duration typically extends for two to four weeks depending on the clinical syndrome and response to therapy. Potential side effects include gastrointestinal upset and, in young animals, tooth discoloration if given during dental development. Doxycycline should be given with food and followed by water to reduce the risk of esophageal irritation.

Fluoroquinolones such as enrofloxacin or marbofloxacin provide an alternative when tetracyclines are contraindicated or ineffective. These drugs achieve good tissue penetration and are effective against most mycoplasma species. Fluoroquinolones are generally avoided in growing puppies due to potential cartilage damage but may be appropriate when other options are limited. Azithromycin and other macrolides also have activity against mycoplasma and may be selected based on specific case factors or susceptibility results when available.

Supportive care complements antibiotic therapy and addresses symptoms while awaiting infection resolution. Dogs with respiratory infections may benefit from humidification, rest, and cough suppressants in some cases, though cough suppressants are avoided when productive coughing helps clear secretions. Anti-inflammatory medications may help dogs with polyarthritis, though caution is warranted regarding potential immunosuppressive effects. Fluid therapy and nutritional support are provided as needed for dogs with systemic illness or decreased intake.

Treatment of concurrent infections is important since mycoplasma often co-occurs with other pathogens. Respiratory mycoplasma infection frequently accompanies viral infections such as parainfluenza, adenovirus, or canine influenza, and secondary bacterial infections with conventional organisms may develop. Comprehensive treatment addressing all identified pathogens optimizes outcomes. Bordetella bronchiseptica commonly co-infects with mycoplasma in kennel cough cases and may require additional antibiotic coverage.

Monitoring response to treatment helps guide duration and identifies cases requiring modification of the treatment plan. Clinical improvement typically begins within several days of starting appropriate antibiotic therapy. Persistence of symptoms beyond expected timeframes prompts reassessment, potentially including repeat diagnostic testing to confirm initial diagnosis and evaluate for resistant organisms or concurrent conditions. Some dogs with chronic mycoplasma infection, particularly polyarthritis, may require extended treatment courses or experience relapses requiring additional therapy.

Recovery from mycoplasma infection in dogs is generally favorable with appropriate antibiotic therapy, though the timeline and completeness of recovery varies depending on the clinical syndrome and individual patient factors. Most dogs with uncomplicated respiratory or urogenital mycoplasma infections recover fully within two to four weeks of starting treatment. More complex cases involving joint disease or immunocompromised patients may require longer treatment and recovery periods.

The recovery timeline for respiratory mycoplasma infection typically follows the pattern seen with other causes of canine infectious respiratory disease complex. Coughing gradually decreases over one to two weeks as the infection resolves, though a mild cough may persist for several weeks even after the infection has cleared due to residual airway irritation. Dogs should be kept calm and rested during recovery to minimize coughing triggered by excitement or exertion. Return to normal activity is appropriate once symptoms have resolved and the treatment course is completed.

Urogenital mycoplasma infections require completion of the full antibiotic course to clear organisms from the reproductive or urinary tract tissues where they reside. Symptoms typically improve within days of starting treatment, but premature discontinuation of antibiotics risks treatment failure and recurrence. Follow-up urinalysis or culture may be recommended after completing treatment to confirm clearance, particularly for dogs with history of recurrent urinary tract infections. Breeding should be postponed until infection is confirmed cleared in dogs intended for reproduction.

Recovery from mycoplasma polyarthritis often takes longer than recovery from respiratory or urogenital infections due to the protected nature of joint infections and the time required for joint inflammation to resolve. Lameness typically begins improving within one to two weeks of starting treatment, but full resolution may take several weeks to months. Some dogs experience residual joint stiffness or intermittent lameness even after infection has cleared. Physical therapy and controlled exercise support joint recovery. Recurrence of polyarthritis can occur and may require additional or prolonged treatment.

Factors influencing recovery and prognosis include the dog's overall immune status, presence of concurrent infections or diseases, and owner compliance with treatment protocols. Dogs with robust immune function generally recover more quickly and completely than immunocompromised animals. Co-infections may complicate recovery and require additional treatment. Completing the full prescribed antibiotic course is essential for successful treatment, as insufficient duration allows surviving organisms to repopulate and potentially develop resistance.

Preventing mycoplasma infection in dogs involves strategies to reduce exposure, minimize stress and crowding that facilitate transmission, and maintain optimal immune function. No vaccines against mycoplasma are available for dogs, making environmental management and general health maintenance the primary prevention approaches. Understanding transmission routes and risk factors enables owners and facility managers to implement practical measures reducing infection risk.

Reducing exposure in high-risk environments forms the foundation of mycoplasma prevention. Kennels, shelters, and boarding facilities should maintain adequate ventilation to reduce airborne pathogen concentrations and prevent buildup of respiratory droplets. Avoiding overcrowding allows dogs adequate space and reduces stress that compromises immune function. Isolation of sick dogs prevents transmission to healthy animals. Regular cleaning and disinfection of shared spaces, bowls, and equipment reduces environmental contamination, though mycoplasmas survive poorly outside hosts compared to some pathogens.

Quarantine protocols for new arrivals in multi-dog facilities provide time to identify infections before exposing resident populations. New dogs ideally undergo a quarantine period of two to three weeks during which they are monitored for respiratory symptoms or other signs of infectious disease. This practice is particularly important for facilities housing immunocompromised dogs or pregnant females where mycoplasma infection could have serious consequences. Testing high-risk new arrivals for mycoplasma before introduction may be warranted in some circumstances.

Maintaining optimal immune function helps dogs resist infection when exposed to mycoplasma. Good nutrition, appropriate exercise, routine veterinary care, and stress minimization all support healthy immune responses. Keeping vaccinations current protects against viral respiratory pathogens that compromise mucosal defenses and predispose to secondary mycoplasma infection. Managing chronic diseases and avoiding unnecessary immunosuppressive medications maintains the immune surveillance that normally keeps commensal mycoplasmas in check.

Breeding management considerations address reproductive mycoplasma infections. Testing breeding dogs for mycoplasma before breeding allows identification and treatment of infected animals, reducing transmission to mates and offspring. Avoiding breeding dogs with history of unexplained infertility, abortion, or weak puppies until mycoplasma has been ruled out protects breeding programs. Good hygiene during breeding and whelping reduces contamination opportunities. These practices are particularly important for commercial breeding operations where mycoplasma infection can cause significant reproductive losses.

Managing daily life with a dog being treated for or prone to mycoplasma infection involves attention to treatment compliance, environmental factors, and monitoring for recurrence. While most mycoplasma infections resolve with appropriate treatment and do not cause long-term problems, some dogs experience chronic or recurrent disease requiring ongoing management. Working with your veterinarian to develop an appropriate care plan ensures the best outcomes for affected dogs.

Medication administration during treatment requires consistency to achieve and maintain effective drug levels. Antibiotics for mycoplasma infection are typically given once or twice daily for several weeks. Setting reminders helps ensure doses are not missed. Doxycycline should be given with food and followed by water to reduce the risk of esophageal irritation. Completing the full prescribed course is essential even when symptoms have resolved, as premature discontinuation risks treatment failure and potential antibiotic resistance development.

Environmental management during treatment and recovery supports healing and reduces reinfection risk. Keeping treated dogs separated from other dogs, particularly in multi-dog households or facilities, prevents transmission during the infectious period. Regular cleaning of bedding, bowls, and living areas reduces environmental contamination. Good ventilation and humidity control support respiratory health. Minimizing stress through maintaining normal routines and avoiding major changes during recovery supports immune function.

Activity modification may be necessary depending on the clinical syndrome. Dogs recovering from respiratory mycoplasma infection should have exercise limited to avoid triggering coughing fits and allow respiratory tissues to heal. Dogs with polyarthritis require careful exercise management, with activity increased gradually as joint symptoms resolve. Avoiding strenuous exercise, jumping, and rough play protects healing joints. Swimming or controlled leash walking may be appropriate low-impact activities during recovery.

Monitoring for recurrence ensures prompt intervention if mycoplasma infection returns. Owners should remain alert for symptoms similar to those that prompted initial diagnosis. Respiratory infections may produce coughing and nasal discharge. Urinary tract involvement causes urination changes. Joint disease produces lameness and stiffness. Early veterinary attention when symptoms recur allows prompt diagnosis and treatment, preventing progression to more severe disease. Some dogs with history of mycoplasma infection may benefit from periodic screening, particularly breeding animals or those with recurrent infections.

Long-term considerations for dogs with chronic or recurrent mycoplasma infection may include ongoing monitoring, periodic preventive treatment, or lifestyle modifications reducing reinfection risk. Dogs with immunodeficiency face higher recurrence risk and may require special management. Discussion with your veterinarian about long-term prognosis and management options helps establish realistic expectations and appropriate care plans for dogs that do not achieve permanent cure with initial treatment.

Mycoplasma infection can affect any dog regardless of breed, and no specific breeds are known to have inherent genetic susceptibility or resistance to these organisms. The risk of developing mycoplasma-related disease relates primarily to environmental exposure factors and immune status rather than breed genetics. However, certain breed-associated factors may indirectly influence mycoplasma infection risk through effects on immune function or lifestyle factors that affect exposure.

Brachycephalic breeds including Bulldogs, Pugs, French Bulldogs, and Boston Terriers have anatomical differences affecting their respiratory tracts that may influence respiratory infection susceptibility in general. The narrowed airways, elongated soft palates, and other features of brachycephalic airway syndrome can compromise respiratory defenses and potentially increase vulnerability to respiratory pathogens including mycoplasma. Additionally, these breeds may show more significant clinical symptoms from respiratory infections that cause only mild disease in dogs with normal airway anatomy.

Breeds used heavily in showing, breeding, or performance activities may face increased mycoplasma exposure through participation in events where many dogs congregate. Popular show breeds attend numerous events where respiratory infections spread readily. Working breeds in kennel environments, whether police dogs, sled dogs, or hunting dogs housed in groups, experience crowding and stress that facilitates mycoplasma transmission. Racing Greyhounds have historically experienced significant kennel cough problems including mycoplasma-associated disease.

Breeds with known predisposition to immune-mediated diseases or those frequently receiving immunosuppressive medications may experience increased susceptibility to opportunistic mycoplasma infections. When immune function is compromised by disease or treatment, normally commensal mycoplasmas can become pathogenic. This represents an acquired risk factor rather than true breed susceptibility to mycoplasma itself. Any dog receiving immunosuppressive therapy should be monitored for signs of opportunistic infections including mycoplasmosis.

Mycoplasma infection in dogs frequently coexists with or must be differentiated from various other conditions affecting the respiratory tract, urogenital system, joints, and eyes. Understanding these related conditions helps ensure comprehensive diagnostic evaluation and appropriate treatment addressing all contributing factors to clinical disease.

Canine infectious respiratory disease complex (CIRDC), commonly known as kennel cough, represents the most important related condition for respiratory mycoplasma infection. This syndrome involves multiple pathogens including Bordetella bronchiseptica, canine parainfluenza virus, canine adenovirus type 2, canine respiratory coronavirus, canine influenza virus, and others in addition to mycoplasma. Affected dogs typically harbor multiple pathogens simultaneously, making it difficult to attribute symptoms to any single organism. Comprehensive treatment may need to address multiple infectious agents. Vaccination against preventable components of CIRDC provides partial protection against this syndrome.

Urinary tract infections caused by conventional bacteria present similarly to mycoplasma urinary infections and may coexist with mycoplasma involvement. Escherichia coli and other common uropathogens are identified through routine urine culture, while mycoplasma requires specialized testing. Recurrent urinary tract infections not responding to appropriate antibiotic therapy based on culture and sensitivity results should prompt mycoplasma testing. Some dogs have concurrent infection with both conventional bacteria and mycoplasma, requiring treatment effective against both.

Immune-mediated polyarthritis produces joint symptoms similar to mycoplasma polyarthritis and must be differentiated through appropriate diagnostic testing. Immune-mediated joint disease involves inappropriate immune responses attacking joint tissues rather than infection. Treatment differs significantly, with immune-mediated disease requiring immunosuppressive therapy that would be inappropriate and potentially harmful for infectious arthritis. Joint fluid analysis and culture or PCR testing distinguish these conditions.

Other causes of conjunctivitis including viral infections, bacterial infections with conventional organisms, allergies, and anatomical abnormalities such as entropion must be considered in dogs with eye symptoms potentially attributable to mycoplasma. Many dogs with mycoplasma conjunctivitis have concurrent infections with other organisms. Chlamydophila infection can produce similar eye disease. Comprehensive ophthalmic examination and appropriate testing ensure accurate diagnosis and effective treatment.